Skip to content

Arvinas ARVN Collaboration contract asset and other assets

Collaboration contract asset and other assets at other companies

Monte Rosa Therapeutics, Inc. logo
Monte Rosa Therapeutics, Inc.GLUE
$0
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$9.91M-47.6%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
$20.51M
Alumis Inc. logo
Alumis Inc.ALMS
$1.74M
Theravance Biopharma logo
Theravance BiopharmaTBPH
$15.58M+1.5%
Kura Oncology logo
Kura OncologyKURA
$12.5M-11.4%

Other financials

Income statement

See full
Revenue$15.6M-91.7%
Operating income-$63.8M-189%
Net income-$57.6M-169%
EPS (diluted)-$0.90-179%

Balance sheet

See full
Cash & equivalents$87.3M+7.8%
Total debt$8.6M-19.6%
Total equity$386.8M-41.4%
Total assets$647.5M-35.3%

Cash flow

See full
Operating cash flow-$69.2M+22.2%
CapEx$1.3M+225%
Free cash flow-$70.5M+21.1%

Valuation

See full
Market cap$518.11M-4.6%
Enterprise value$439.41M-7.1%
P/S5.8×+4.5×

Profitability

See full
Operating margin-283.8%-310pp
Net margin-247.5%-260pp
FCF margin-287.4%

Returns & leverage

See full
Return on equity-42.3%-53.5pp
Debt / equity0.0×
Current ratio5.4×+0.9×

Where this comes from

Reported directly by Arvinas in its filing.

Tagged under the XBRL concept arvn:CollaborationContractAssetAndOtherAssets.

The official record: Arvinas’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Arvinas's collaboration contract asset and other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Arvinas's collaboration contract asset and other assets?
Arvinas (ARVN) reported collaboration contract asset and other assets of $3.5M in Q1 2026.
How has Arvinas's collaboration contract asset and other assets changed year-over-year?
Arvinas's collaboration contract asset and other assets decreased by 27.1% year-over-year, from $4.8M to $3.5M.
What does collaboration contract asset and other assets mean?
This metric represents the long-term portion of assets arising from strategic research and development partnerships, including deferred contract considerations and other non-current intangible or financial assets. It reflects the value of future economic benefits expected from collaboration agreements that extend beyond the current fiscal year. Investors use this to assess the company's long-term pipeline value and the potential future revenue streams tied to external pharmaceutical partnerships.